Gene Therapy Halts Progression of Young Boy’s Rare Genetic Condition


Register for free to listen to this article

Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Michael has spastic paraplegia type 50 (SPG50), an “ultra-rare” progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, progressive paralysis of all four limbs, and is typically fatal by adulthood. Approximately 80 children around the world are affected by this genetic condition.

In a bid to slow the progression of the condition, a clinical research team at SickKids administered a first single-patient gene therapy to Michael less than three years after his initial diagnosis. 

Today, the groundbreaking clinical trial published in Nature Medicine documents Michael’s journey in the 12 months following the procedure, along with the novel impact this trial holds for the future of genetic medicine in Canada.

What is gene therapy?

Gene therapy is a way of delivering a healthy copy of a gene into the cells of a person who has a faulty gene(s). In Michael’s case, SPG50 is caused by two pathogenic variants in a gene called AP4M1.

Led by Dr. Jim Dowling, Staff Physician in the Division of Neurology and Senior Scientist in the Genetics & Genome Biology program at SickKids, the clinical research team delivered the healthy AP4M1 gene into Michael’s spinal fluid, which carried the gene directly to the nerve cells.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“While these ultra-rare diseases are unique, our workflow provides a road map for gene therapies that could help many of the thousands of children in Canada with rare genetic conditions,” says Dowling.

Thanks to a multi-center collaboration with doctors and companies in the U.S. and Canada to coordinate the research, development, and manufacturing of a gene replacement therapy, the team were, remarkably, able to administer the gene therapy treatment to Michael within three years of diagnosis.

Michael’s journey

In the 12 months after he received the treatment, Michael experienced no serious side effects and, contrary to the hallmark of neurodegenerative conditions like SPG50, his condition does not seem to be progressing further.

He also began to show potential signs of improvement. For the first time, Michael was able to stand with his heels on the ground. He also experienced improvements in some aspects of his neurodevelopment.

“When we heard that Michael had been diagnosed with this terrible disease, our world fell apart. We were lost and broken as a family,” says Michael’s parents, Terry and Georgia. “Thankfully, we had an amazing team at SickKids and a supportive community that lifted us up and gave us the confidence to raise millions of dollars and create a therapy, not only for Michael, but for other children affected by this disease for generations to come.”

The future of gene therapy in Canada

The clinical research team continues to follow Michael’s progress, but the trial provides important initial evidence of the safety and efficacy of gene therapy to reduce or halt the progression of SPG50.

Importantly, the results also highlight how gene therapy can be developed quickly and personalized for individual patients with rare genetic conditions. They hope that this approach can be used for other conditions in the future to help achieve Precision Child Health, a movement at SickKids to deliver individualized care for every patient.

Reference: Dowling JJ, Pirovolakis T, Devakandan K, et al. AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient. Nat Med. 2024. doi: 10.1038/s41591-024-03078-4

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.


Leave a Reply

Your email address will not be published. Required fields are marked *